Abstract
References
Articles referenced by this article (25)
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
Neuropharmacology, (7):1110-1118 2002
MED: 12504917
Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Br J Pharmacol, (2):500-506 2001
MED: 11159700
Some puzzling pharmacological effects of monoamine oxidase inhibitors.
Adv Biochem Psychopharmacol, 393-408 1972
MED: 5066229
Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).
Pharmacotherapy, (12):1250-1258 2014
MED: 25314256
Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties.
Med Res Rev, (3):323-358 1984
MED: 6379342
Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.
Br J Pharmacol, (1):65-74 1981
MED: 6793119
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
J Neurochem, (5):1359-1365 1986
MED: 2420928
Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Br J Pharmacol, (5):999-1013 2013
MED: 23992249
Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor.
Psychopharmacologia, (1):118-123 1970
MED: 4943186
The effect of age on the activity and molecular properties of human brain monoamine oxidase.
J Neural Transm, (1-2):1-20 1980
MED: 7441234
Show 10 more references (10 of 25)
Citations & impact
Impact metrics
Alternative metrics
Discover the attention surrounding your research
https://www.altmetric.com/details/165712359
Article citations
The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
Int J Mol Sci, 22(11):5999, 01 Jun 2021
Cited by: 17 articles | PMID: 34206133 | PMCID: PMC8199574
Review
Free full text in Europe PMC
Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial.
Front Pharmacol, 11:571747, 03 Dec 2020
Cited by: 3 articles | PMID: 33364947 | PMCID: PMC7750811
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
J Neural Transm (Vienna), 108(8-9):985-1009, 01 Jan 2001
Cited by: 80 articles | PMID: 11716151
Monoamine oxidase and their inhibitors. Preface.
Int Rev Neurobiol, 100:xi-xv, 01 Jan 2011
Cited by: 0 articles | PMID: 21971011
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
Exp Neurol, 187(2):455-459, 01 Jun 2004
Cited by: 77 articles | PMID: 15144871
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Prog Neurobiol, 92(3):330-344, 19 Jun 2010
Cited by: 85 articles | PMID: 20600573
Review